Laquinimod is an orally-available. quinolinone-based, broad spectrum immunomodulator with anti-inflammatory activity, most likely by effecting a T-helper cell 1 to 2 cytokine shift. [1] Additionally it reduces antigen presentation and the effect on migration of T-cells. Laquinimod is also believed to provide a neuroprotective effect and may have application to relapsing-remitting multiple sclerosis (RRMS). [2]In animal models for multiple sclerosis, Laquinimod reversed established relapsing remitting experimental autoimmune encephalomyelitis (RR EAE) and was associated with reduced CNS inflammation, decreased Th1 and Th17 responses, and an increase in regulatory T cells. [3]
Technical information:
| Chemical Formula: | C19H17ClN2O3 | |
| CAS #: | 248281-84-7 | |
| Molecular Weight: | 356.8 | |
| Purity: | > 98% | |
| Appearance: | White solid | |
| Chemical Name: | 5-chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide | |
| Solubility: | Up to 22 mM in DMSO | |
| Synonyms: | ABR-215062, ABR 215062, ABR215062, Laquinimod |
Shipping Condition: The product is shipped in a glass vial at ambient temperature.Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.
Reference:
| 1. | "Laquinimod for relapsing-remitting multiple sclerosis" National Horizon Scaning Centre technology summary, Aug. 2011. |
| 2. | West et al., Profile of oral laquinimod and its potential in the treatment of multiple sclerosis. Degenerative Neurological Muscular Disease 2011, 1, 25-32. |
| 3. | Schulze-Topphoff et al., Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS ONE 2012, 7(3), e33797. Pubmed ID:22479444 |
Other Information:
Product Specification (pdf) MSDS (pdf) Certificate of Analysis is available upon request.
